Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263210, C514S263220, C514S263230, C514S263240, C544S276000, C544S277000, C544S321000, C544S323000, C544S324000, C544S326000, C544S328000, C544S332000, C549S396000, C549S399000, C549S404000
Reexamination Certificate
active
07915268
ABSTRACT:
The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory diseases, mast cell mediated disease and transplant rejection. The compounds of the general formula I shown below, in which Q is selected from the group consisting of CX and nitrogen; and A is chosen from the group consisting of alkyl, heterocyclyl, aryl, substituted alkyl, substituted heterocyclyl, substituted aryl, and halogen:
REFERENCES:
patent: 4247556 (1981-01-01), von Bebenburg et al.
patent: 4813998 (1989-03-01), Van Lommen et al.
patent: 5493011 (1996-02-01), Jung et al.
patent: 5705625 (1998-01-01), Civin et al.
patent: 5916792 (1999-06-01), Civin et al.
patent: 6313129 (2001-11-01), Uckun et al.
patent: 6372740 (2002-04-01), Murata et al.
patent: 6432947 (2002-08-01), Arnaiz et al.
patent: 6452005 (2002-09-01), Uckun et al.
patent: 6506738 (2003-01-01), Yu et al.
patent: 6582357 (2003-06-01), Ouchi et al.
patent: 2004/0116435 (2004-06-01), Eriksson et al.
patent: 2004/0116449 (2004-06-01), Changelian
patent: 2004/0157739 (2004-08-01), Ahrens et al.
patent: 2005/0032725 (2005-02-01), Rao et al.
patent: 2007/0021443 (2007-01-01), Ohlmeyer et al.
patent: 2007/0253896 (2007-11-01), Le Brazidec et al.
patent: 2008/0085898 (2008-04-01), Lu et al.
patent: 2008/0085909 (2008-04-01), Roughton et al.
patent: 2008/0119496 (2008-05-01), Ohlmeyer et al.
patent: 2008/0207613 (2008-08-01), Styles et al.
patent: 2008/0214580 (2008-09-01), Neagu et al.
patent: 2008/0220256 (2008-09-01), Bhattacharya et al.
patent: 2008/0254029 (2008-10-01), Yanni et al.
patent: 2008/0287468 (2008-11-01), Ohlmeyer et al.
patent: 2009/0023723 (2009-01-01), Cole et al.
patent: 2009/0069289 (2009-03-01), Neagu et al.
patent: 2009/0281075 (2009-11-01), Roughton et al.
patent: 2010/0130516 (2010-05-01), Eriksen et al.
patent: 2238689 (1997-05-01), None
patent: 2841209 (1979-04-01), None
patent: 10 2005 042742 (2007-03-01), None
patent: 0 277 384 (1988-08-01), None
patent: 0 807 629 (1997-11-01), None
patent: 1043324 (2000-10-01), None
patent: 1221444 (2002-07-01), None
patent: 07075798 (1995-03-01), None
patent: 2004 217582 (2004-04-01), None
patent: 99/41248 (1999-08-01), None
patent: 00/12089 (2000-03-01), None
patent: 01/19828 (2001-03-01), None
patent: WO 02/055521 (2002-07-01), None
patent: 03/051277 (2003-06-01), None
patent: 2004/043386 (2004-05-01), None
patent: 2004/099204 (2004-11-01), None
patent: WO 2005/023761 (2005-03-01), None
patent: 2005/066156 (2005-07-01), None
patent: 2006/069080 (2006-06-01), None
patent: WO 2006/074985 (2006-07-01), None
patent: WO 2006/087538 (2006-08-01), None
patent: WO 2006/091737 (2006-08-01), None
patent: 2006/096270 (2006-09-01), None
patent: 2006/108103 (2006-10-01), None
patent: 2007/035873 (2006-10-01), None
patent: WO 2007/058990 (2007-05-01), None
patent: WO 2007/140222 (2007-12-01), None
patent: WO 2007/146712 (2007-12-01), None
patent: WO 2008/043019 (2008-04-01), None
patent: WO 2008/043031 (2008-04-01), None
patent: WO 2008/051493 (2008-05-01), None
patent: WO 2008/051494 (2008-05-01), None
patent: WO 2008/143674 (2008-11-01), None
patent: WO 2009/062059 (2009-05-01), None
Cetkovic-Cvrlje et al., “Dual Targeting of Burton's Tyrosine kinase and Janus kinase 3 with Rationally Designed Inhibitors Prevents Graft-Versus-Host Disease (GVHD),”British Journal of Haematology, vol. 126, pp. 821-827 (2004).
Cetkovic-Cvrlje et al., “Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases,”Arch. Immunol. Ther. Exp., vol. 52, pp. 69-82 (2004.).
Changelian et al., “Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor,”Science, vol. 302, pp. 875-878 (2003).
O'Shea, J.J., “Cytokine signaling: new insights and new opportunities for therapeutic intervention?”,Arthristis Res., vol. 3(Suppl A): L018 (2001).
Ortmann et al., “Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation,”Arthritis Res., ,vol. 2, pp. 16-32 (2000).
Yamaoka et al., “The Janus kinases (Jaks),”Genome Biology, vol. 5:253, pp. 253.1-253.6 (2004).
Uckun et al., “Structure-based Design of Novel Anticancer Agents,”Current Cancer Drug Targets, vol. 1(1), pp. 59-71 (2001).
Kawahara et al., “Critical role of the interleukin 2 (IL-2) receptory-chain associated Jak3 in the IL-2-induced c-fosand c-myc, but notbcl-2, gene induction,”Proc. Natl. Acad. Sci., vol. 92, pp. 8724-8728 (1995).
O'Shea et al., “A New Modality for Immunosuppression: Targeting the Jak/Stat Pathway,”Nature Reviews, vol. 3, pp. 555-564 (2004).
Papageorgiou et al., “Is Jak3 a new drug target for immunomodulation-based therapies?”TRENDS in Pharmacological Sciences, vol. 25(11), pp. 558-562 (2004).
Lin et al., “Constitutive Activation of Jak3/Stat3 in Colon Carcinoma Tumors and Cell Lines”,American Journal of Pathology, vol. 167(4), pp. 969-980 (2005).
Dana et al, “Role of Immunity and Inflammation in Corneal and Ocular Surface Disease Associated with Dry Eye,”Lacrimal Gland, Tear Film and Dry Eye Syndromes 3, pp. 729-738 (2002).
Nagelhout et al., “Preservation of Tear Film Integrity and Inhibition of Corneal Injury by Dexamethasone in a Rabbit Model of Lacrimal Gland Inflammation-Induced Dry Eye,”Journal of Ocular Pharmacology and Therapeutics, vol. 21(2), pp. 139-148 (2005).
Pflugfelder, S., “Perspective Anti-inflammatory Therapy for Dry Eye,”American Journal of Ophthalmology, vol. 137(2), pp. 337-342 (2004).
Amin et al., “Inhibition of Jak3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma,”Oncogene, vol. 22, pp. 5399-5407 (2003).
Harrington et al., “VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo,”Nature Medicine, vol. 10(3), pp. 262-267 (2004).
Jung et al., “Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase,” American Chem Soc., pp. 1-16 (2005).
Frantz, S., “Playing Dirty”,Nature, vol. 437, pp. 942-943 (2005).
Martinez-Lostao et al., “Role of the STAT1 pathway in apoptosis induced by fludarabine and Jak kinase inhibitors in B-cell chronic lymphocytic leukemia,”Leuk Lymphoma, vol. 46(3), pp. 435-442 (2005), Abstract only (PMID: 15621835).
Lai et al., “Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma,”Human Pathology, vol. 36, pp. 939-944 (2005).
Pearson, H., “Designer transplant drug shows promise in monkeys,”News&Nature(2003).
Goldberg et. al., “Optimization of 2-Phenylaminoimidazo [4,5-h]isoquinolin-9-ones: Orally Active Inhibitors of Ick Kinase,”Journal of Medical Chem., vol. 46, pp. 1337-1349.
International Search Report from International Application No. PCT/US2006/012824.
International Search Report from International Application No. PCT/US2006/061004.
Beijersbergen van Henegouwen GM et al., Hydrolysis of RRR0alpha-tocopheryl acetate (vitamin # acetate) in the skin and its UV protecting activity (an in vivo study with the rat)J Photochem Photobiol, Jul. 29, 2005, vol. 1, pp. 45-51.
International Search Report from International Application No. PCT/US2007/080447.
International Search Report from International Application No. PCT/US2007/080464.
International Search Report and Written Opinion from International Application No. PCT/US2007/081232.
International Search Report and Written Opinion from International Application No. PCT/US2007/069530.
Hirota et all, “Synthesis and Biological Evaluation of 2,8-Disubstituted 9-Benzyladenines: Discovery of 8-Mercaptoadenines as Potent Interferon-Inducers,”Bioorganic&Medicinal Chemistry 11, 2003, pp. 2715-2722.
Written Opinion corresponding to PCT/US2007/080447.
Written Opinion corresponding to PCT/US2007/080464.
Written Opini
Bohnstedt Adolph
Kingsbury Celia
Lu Yingchun
Ohlmeyer Michael
Paradkar Vidyadhar
Berch Mark L
Sabnis Ram W.
Wyeth LLC
LandOfFree
8-substituted 2-(benzimidazolyl)purine derivatives for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-substituted 2-(benzimidazolyl)purine derivatives for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-substituted 2-(benzimidazolyl)purine derivatives for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2665826